Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $810.00 by Analysts at Guggenheim

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by Guggenheim from $940.00 to $810.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other research reports. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective on the stock. TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Finally, Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $892.60.

Regeneron Pharmaceuticals Trading Up 2.6 %

Shares of Regeneron Pharmaceuticals stock opened at $605.61 on Thursday. Regeneron Pharmaceuticals has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $66.21 billion, a P/E ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a fifty day moving average of $626.49 and a 200 day moving average of $709.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $9.55 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares in the last quarter. Finally, Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.